Zacks: Analysts Set $4.50 Price Target for ContraVir Pharmaceuticals Inc (CTRV)
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1 year consensus price target of $4.50 for the company, according to Zacks. Zacks has also assigned ContraVir Pharmaceuticals an industry rank of 101 out of 265 based on the ratings given to its competitors.
Separately, Maxim Group reiterated a “buy” rating and set a $4.00 price objective on shares of ContraVir Pharmaceuticals in a report on Thursday, August 24th.
Shares of ContraVir Pharmaceuticals (CTRV) traded down $0.01 during mid-day trading on Thursday, hitting $0.34. 900,100 shares of the stock traded hands, compared to its average volume of 940,285. ContraVir Pharmaceuticals has a 1-year low of $0.32 and a 1-year high of $2.07.
ContraVir Pharmaceuticals Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.